FDA Approves Bristol Myers' Orencia As First Drug To Prevent Graft-Versus-Host DiseaseBenzinga • 12/16/21
Bristol Myers Squibb (BMY) Outpaces Stock Market Gains: What You Should KnowZacks Investment Research • 12/16/21
U.S. Food and Drug Administration Approves Orencia® (abatacept) in Combination with a Calcineurin Inhibitor and Methotrexate for the Prevention of Acute Graft Versus Host Disease (aGvHD).Business Wire • 12/15/21
2 High-Yield Dividend Stocks That Can Safeguard Your Portfolio Against InflationThe Motley Fool • 12/14/21
Immatics and Bristol Myers Squibb Enter Into Global Exclusive License for Immatics' TCR Bispecific Program IMA401Business Wire • 12/14/21
Bristol Myers Squibb raises quarterly dividend and adds $15 billion to share buyback programMarket Watch • 12/13/21
Bristol Myers Squibb Announces Dividend Increase and Additional $15 Billion Share Repurchase AuthorizationBusiness Wire • 12/13/21
Bristol Myers Squibb's Breyanzi (lisocabtagene maraleucel) Significantly Improves Outcomes, Showing Superiority Over 20-Year Standard of Care in Second-Line Relapsed or Refractory Large B-cell Lymphoma Based on TRANSFORM Study ResultsBusiness Wire • 12/11/21
Could Bristol Myers Squibb and Johnson & Johnson Have a Powerful New Blood Thinner on the Way?The Motley Fool • 12/04/21